A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback